Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 12, 2021 07:05 ET | Source: Myriad Genetics, Inc.

New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad Genetics’ Prolaris® test to Guide Treatment for Prostate Cancer

SALT LAKE CITY, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today additional data further validating the...
February 11, 2021 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics to Participate in Multiple Upcoming Health and Technology Conferences

SALT LAKE CITY, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it will participate at multiple...
February 08, 2021 07:05 ET | Source: Myriad Genetics, Inc.

GeneSight Psychotropic Test’s Combinatorial Approach Proves Better than Single-Gene Testing at Predicting Patient Outcomes and Medication Blood Levels

New Analysis Published in Psychiatry Research SALT LAKE CITY, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced...
February 02, 2021 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Launches New Vectra® Cardiovascular Risk Assessment for Patients with Rheumatoid Arthritis

SALT LAKE CITY, Feb. 02, 2021 (GLOBE NEWSWIRE) -- To help more patients with rheumatoid arthritis (RA), Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine,...
January 19, 2021 07:05 ET | Source: Myriad Genetics, Inc.

ミリアド･ジェネティクス、BRACAnalysis®診断システムに日本で保険適用を取得

前立腺がんおよび膵がん患者にリムパーザによる治療を利用可能に日本の2万人を超える患者が遺伝子検査対象にソルトレークシティ, Jan. 19, 2021 (GLOBE NEWSWIRE) -- 遺伝子検査とプレシジョン･メディシンのリーダーであるミリアド･ジェネティクス (Myriad Genetics, Inc.) (NASDAQ: MYGN)...
January 19, 2021 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Receives Reimbursement for BRACAnalysis® Diagnostic System in Japan

Patients with Prostate or Pancreatic Cancer to Benefit from Treatment with Lynparza More Than 20,000 Patients in Japan Now Qualify for Genetic Testing SALT LAKE CITY, Jan. 19, 2021 (GLOBE...
January 11, 2021 14:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Forms Strategic Partnership with Illumina in Oncology

Note: Paul Diaz, President & CEO of Myriad Genetics will speak today at the 39th Annual JP Morgan Healthcare Conference at 2:50 p.m. EST accessible via a live audio webcast at the following direct...
January 08, 2021 15:18 ET | Source: Myriad Genetics, Inc.

ミリアド･ジェネティクス、myChoice®診断システムに日本で初めて保険適用を取得、卵巣がん治療にゼジューラ®を利用可能に

ソルトレークシティ発, Jan. 09, 2021 (GLOBE NEWSWIRE) -- 遺伝子検査とプレシジョン･メディシンのリーダーであるミリアド･ジェネティクス (Myriad Genetics, Inc.) (NASDAQ:MYGN) は本日、Myriad...
January 08, 2021 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Receives First Reimbursement Decision for myChoice® Diagnostic System in Japan, Enabling Women with Ovarian Cancer to Benefit from Treatment with Zejula®

SALT LAKE CITY, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it received its first reimbursement...
January 05, 2021 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Provides Transformation Update, Pursues Strategic Alternatives for Autoimmune Business, Realigns International Operations

SALT LAKE CITY, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the substantial completion of its...